Skip to main content

LCD L35093: Immune Globulin

LCD L35093, Immune Globulin, is the Local Coverage Determination that Novitas Solutions, Inc. applies to claims from 11 states plus DC (AR, CO, DC, DE, LA, MD, MS, NJ and others), effective 2023-02-05 and first in force 2015-10-01. The policy text runs 974 words, and its billing and coding article A56786 lists 108 ICD-10-CM codes that support medical necessity for 18 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 108 covered ICD-10-CM codes: the same total as L34007 (First Coast Service Options, Inc., 108 codes, revised 2023-02-05).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Novitas Solutions, Inc.
States and territories
12
AR CO DC DE LA MD MS NJ NM OK PA TX
Revision effective
2023-02-05
Original effective
2015-10-01
Policy text
974 words
Covered ICD-10 codes (articles)
108

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L35093
ContractContractorTypeStates
12101Novitas Solutions, Inc.A and B MACDE
12201Novitas Solutions, Inc.A and B MACDC
12301Novitas Solutions, Inc.A and B MACMD
12401Novitas Solutions, Inc.A and B MACNJ
12501Novitas Solutions, Inc.A and B MACPA
12102Novitas Solutions, Inc.A and B MACDE
12202Novitas Solutions, Inc.A and B MACDC
12302Novitas Solutions, Inc.A and B MACMD
12402Novitas Solutions, Inc.A and B MACNJ
12502Novitas Solutions, Inc.A and B MACPA
12901Novitas Solutions, Inc.A and B MACDC DE MD NJ PA
07102Novitas Solutions, Inc.A and B MACAR
07202Novitas Solutions, Inc.A and B MACLA
07101Novitas Solutions, Inc.A and B MACAR
07201Novitas Solutions, Inc.A and B MACLA
07301Novitas Solutions, Inc.A and B MACMS
07302Novitas Solutions, Inc.A and B MACMS
04111Novitas Solutions, Inc.A and B MACCO
04211Novitas Solutions, Inc.A and B MACNM
04311Novitas Solutions, Inc.A and B MACOK
04411Novitas Solutions, Inc.A and B MACTX
04112Novitas Solutions, Inc.A and B MACCO
04212Novitas Solutions, Inc.A and B MACNM
04312Novitas Solutions, Inc.A and B MACOK
04412Novitas Solutions, Inc.A and B MACTX
04911Novitas Solutions, Inc.A and B MACCO NM OK TX

Billing and coding article A56786: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56786 (Billing and Coding: Immune Globulin) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56786: Billing and Coding: Immune Globulin (Billing and Coding, effective 2026-07-01)

Covered ICD-10-CM codes
108
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
18
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56786
ICD-10-CMDescription (FY2027)
C90.00Multiple myeloma not having achieved remission
C90.02Multiple myeloma in relapse
C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.12Chronic lymphocytic leukemia of B-cell type in relapse
D59.0Drug-induced autoimmune hemolytic anemia
D59.11Warm autoimmune hemolytic anemia
D59.12Cold autoimmune hemolytic anemia
D59.13Mixed type autoimmune hemolytic anemia
D59.19Other autoimmune hemolytic anemia
D69.3Immune thrombocytopenic purpura
D69.41Evans syndrome
D80.0Hereditary hypogammaglobulinemia
D80.1Nonfamilial hypogammaglobulinemia
D80.2Selective deficiency of immunoglobulin A [IgA]
D80.3Selective deficiency of immunoglobulin G [IgG] subclasses
D80.4Selective deficiency of immunoglobulin M [IgM]
D80.5Immunodeficiency with increased immunoglobulin M [IgM]
D80.6Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
D80.7Transient hypogammaglobulinemia of infancy
D80.8Other immunodeficiencies with predominantly antibody defects
D81.0Severe combined immunodeficiency [SCID] with reticular dysgenesis
D81.1Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
D81.2Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
D81.31Severe combined immunodeficiency due to adenosine deaminase deficiency

Procedure codes: J1459 (Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1551 (Injection, immune globulin (cutaquig), 100 mg), J1552 (Injection, immune globulin (alyglo), 500 mg), J1553 (Injection, immune globulin (yimmugo), 100 mg), J1554 (Injection, immune globulin (asceniv), 500 mg), J1555 (Injection, immune globulin (cuvitru), 100 mg), J1556 (Injection, immune globulin (bivigam), 500 mg), J1557 (Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1558 (Injection, immune globulin (xembify), 100 mg), J1559 (Injection, immune globulin (hizentra), 100 mg), J1561 (Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg), J1566 (Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg), J1568 (Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1569 (Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg), J1572 (Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1575 (Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin), J1576 (Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1577 (Injection, immune globulin (qivigy), 100 mg).

Coverage indications, limitations and medical necessity

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

Immune globulin (also referred to as gamma globulin or immunoglobulin) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors that contains antibodies to a wide spectrum of antigens. Immune globulin has been utilized for immune deficiencies identified in individuals with inherited or acquired immunodeficiencies and is used for its capacity in combating infection as a replacement therapy and for its anti-inflammatory and immunomodulating effects. The appropriate use of immune globulin can decrease morbidity and mortality and improve quality of life. 1,2

The focus of this LCD is the United States (U.S.) Food and Drug Administration (FDA) approved indications and the off-label indications for immune globulin where the evidence supports such use. Immune globulin products are not generic drugs and products are not interchangeable. A specific product needs to be matched to patient characteristics to ensure patient safety and a change of product should occur only with the active participation of the prescribing provider. 3

The overall coverage of drugs is addressed in the CMS IOM Publication 100-02, Medicare Benefit Policy Manual , Chapter 15, Sections 50.4.1 and 50.4.2 and includes coverage for FDA-approved drugs and unlabeled use of a drug.

Covered Indications

Immune globulin products will be considered medically reasonable and necessary when administered for treatment of FDA-labeled indications (https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulins 4 ).

Off-label indications for intravenous immune globulin ( IVIG) products will be considered medically reasonable and necessary in the following situations:

• Multiple myeloma for recurrent infections with hypogammaglobulinemia and subprotective antibody levels following immunization against diphtheria, tetanus or pneumococcal infection 1,3,5-7

• Following treatment of lymphoma utilizing B-cell depleting therapies for recurrent infections with hypogammaglobulinemia and subprotective antibody levels following immunization against diphtheria, tetanus or pneumococcal infection 3

• Recipients of hematopoietic stem cell transplants with severe combined immunodeficiency (SCID) or other primary immunodeficiencies who are functionally agammaglobulinemic because of weak B-cell engraftment 3

• Recipients of allogeneic hematopoietic stem cell transplantation with chronic graft versus host disease (GVHD), recurring bacterial infections, and subprotective antibody levels following immunization against diphtheria, tetanus or pneumococcal infection 3

• Human Leukocyte Antigen (HLA) and ABO desensitization protocols for the prevention of acute humoral rejection in renal transplantation 3

• The treatment of antibody mediated solid organ transplant rejection in combination with rituximab and plasma exchange (PE) 3,8

• Treatment of hypogammaglobulinemia in solid organ transplants 3

• Autoimmune hemolytic anemia (AIHA) when other treatment approaches have failed 9-10

• Systemic capillary leak syndrome (SCLS) 11-13

• Guillain-Barré syndrome (GBS) in adults 1,3,14-15

• Moderate to severe myasthenia gravis (MG) 2-3,10,15-18

• Lambert-Eaton myasthenic syndrome (LEMS) in individuals who fail to respond or do not tolerate other treatments 3

• Relapsing-remitting multiple sclerosis (MS) 3,19-22

• Neuromyelitis optica (Devic syndrome) in individuals with severe relapses not responding to corticosteroids and who are not candidates for PE 3

• Stiff-person syndrome (also referred to as stiff-man syndrome) 2-3

• Treatment of autoimmune encephalitis, once infection is ruled out, as an alternative in patients who fail to respond or do not tolerate other treatments 23-27

• Treatment of Susac syndrome in combination with high-dose intravenous corticosteroids 28

• Severe forms of polymyositis resistant to treatment with glucocorticosteroids and immunosuppressants 29-30

• Severe forms of inclusion body myositis with dysphagia and individuals are otherwise treatment-resistant 3,29-33

• Immune mediated necrotizing myopathy resistant to treatment with glucocorticosteroids and immunosuppressants 29-30

• Overlap syndrome with myositis including anti-synthetase syndrome resistant to treatment with glucocorticosteroids and immunosuppressants 29-30

• Severe systemic lupus erythematosus (SLE) in individuals who fail to respond or do not tolerate other treatments 10,30

• Biopsy-proven autoimmune mucocutaneous blistering diseases in individuals who fail to respond or do not tolerate other treatments and individuals with rapidly progressive disease requiring a faster response than conventional therapy (i.e., pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita) 3,30,34-39

• Toxic epidermal necrolysis (TEN) 3,30

• Stevens-Johnson syndrome 3,30

• Severe scleromyxedema 3,30,40-41

• Thyroid eye disease, also referred to as Graves’ disease in patients who have failed treatment with teprotumumab or have contraindications to the use of teprotumumab 3,42-45

Limitations

The following are considered not medically reasonable and necessary:

• The off-label use of subcutaneous immune globulin

• The off-label use of intravenous immune globulin not listed above in the covered indications

AND

Immune globulin for the following:

• Routine use in the immediate peri-transplantation period for the prevention of infection or GVHD following marrow or peripheral blood allogeneic transplantation 3,46

• Acute GVHD with hematopoietic stem cell transplantation in the immediate post-transplantation phase 3

• Hematopoietic stem cell transplantation in the immediate post-transplantation phase with a history of sinusoidal obstructive syndrome 3,46

• Cord blood stem cell transplantation for children or adults 3

• Polyneuropathy associated with IgM monoclonal gammopathy 10

• Idiopathic neuropathies 10

• Brachial plexopathy 10

• Adrenoleukodystrophy 10

• Amyotrophic lateral sclerosis 10

• Critical illness polyneuropathy 10

• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) 10

Please refer to the CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 4, Section 250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases for additional limitations.

Provider Qualifications

Services will be considered medically reasonable and necessary when all aspects of care are within the scope of practice of the provider’s professional licensure; and when all procedures are performed by appropriately trained providers in the appropriate setting.

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

Summary of evidence (opening)

A literature search was conducted for evidence-based guidelines and appropriate use criteria for immune globulin. The literature search was filtered to locate articles within five-ten years, full-text articles, clinical trials, and systematic reviews.

Multiple guidelines and appropriate use criteria are available for utilization of immune globulin. The goal of immune globulin therapy is to improve health outcomes of patients. In general, improved health outcomes of interest include patient mortality and morbidity, as well as patient quality of life and function.

History/Background

Immunoglobulins (also referred to as immune globulin or gamma globulin) are antibodies produced by differentiated B cells called plasma cells. The immunoglobulin molecule has a distinctive structure that has the ability to recognize specific antigenic determinants. The immune globulin formulations are generated from the pooled human plasma of thousands of healthy donors, which allows the immune globulin formulations to include a large and diverse antibody collection. The supply of immune globulin is limited as it depends on donated plasma. Therefore, it is imperative for healthcare providers to understand current levels of evidence to support immune globulin therapy as the appropriate use of immune globulin can decrease morbidity and mortality and improve quality of life. Immune globulin is a key component in the treatment for individuals with primary immunodeficiency disease affecting the humoral immune system. Intravenous formulations are significant in the treatment of other conditions as well, some for which have no available alternative treatments. 1-2

The contractor cites 61 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2023-02-05
MCD version
114
Derived from
L32712

The contractor lists one National Coverage Determination as related: NCD 250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59283 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Novitas Solutions, Inc. hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L35093 cover?

Immune globulin (also referred to as gamma globulin or immunoglobulin) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors that contains antibodies to a wide spectrum of antigens. Immune globulin has been utilized for immune deficiencies identified in individuals with inherited or acquired immunodeficiencies and is used for its capacity in combating infection… The full 974-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L35093 apply to?

Novitas Solutions, Inc. applies it to Medicare claims in 11 states plus DC: AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L35093?

The companion billing and coding article A56786 lists 108 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L35093?

A denial under LCD L35093 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56786's 108 covered diagnosis codes, then file a redetermination with Novitas Solutions, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.